ImmunityBio Lands BCG Deal as Anktiva FDA Ruling Nears

NEW YORK, May 18 —

ImmunityBio is acquiring U.S. rights to the Tokyo strain of BCG, a tuberculosis vaccine repurposed as a bladder cancer treatment, in a deal aimed at a supply shortage that has persisted for a decade. Separately, traders are positioning ahead of a pending FDA ruling on Anktiva, the company's lead immunotherapy. One outlet placed the ruling against the backdrop of "Trump's FDA turmoil." Both events are landing at the same time.

The BCG Acquisition

BCG, Bacillus Calmette-Guérin, is the standard first-line treatment for high-risk non-muscle-invasive bladder cancer. The U.S. has faced recurring supply gaps from its primary manufacturer for years. Acquiring rights to the Tokyo strain, as news reports dated May 17 describe, gives ImmunityBio access to an alternative domestic supply source. The deal is explicitly framed as targeting that decade-long shortage.

The transaction predates the headlines. In an 8-K filed March 31, 2026, ImmunityBio disclosed entry into a Material Definitive Agreement and the creation of a Material Direct Financial Obligation, alongside a Regulation FD disclosure and an Other Events item. The filing placed a financially binding commitment on the books six weeks before the deal surfaced in the press.

The Anktiva Moment

Anktiva is ImmunityBio's IL-15 superagonist, designed for BCG-unresponsive bladder cancer patients in combination with BCG. News reports from May 17 and 18 describe traders bracing for the FDA ruling. Approval starts the commercial clock; a rejection or delay pushes back revenue from the company's core product.

ImmunityBio is already preparing for approval. A May 16 report cited the company declaring "all systems go" for manufacturing at its Dunkirk facility. A manufacturing readiness declaration before a ruling signals commercial preparedness and sets investor expectations. An April 6 Regulation FD 8-K shows the company was in active investor communications during that same window.

Revenue Growth, With a Footnote

The financials point in two directions. Revenue hit $0.14 billion, up 167.6% year-over-year, on a 99.3% gross margin — the cost structure of a high-value biologic. Losses have narrowed for three straight quarters. The most recent quarter came in at -$0.06 against a consensus estimate of roughly -$0.10. The prior quarter was -$0.07 versus a -$0.10 estimate. The quarter before that matched the -$0.10 estimate exactly. Losses per share have compressed over three consecutive reporting periods.

The complication is free cash flow. Negative $194 million annually means the company burns cash faster than it collects revenue. The March 31 filing's new Material Direct Financial Obligation adds to that pressure. ImmunityBio filed earnings 8-Ks on both May 7, 2026 and April 9, 2026, each carrying the most recent detail on operating results and balance sheet changes.

At $7.97, the stock trades at roughly half the consensus analyst price target of $15.50. That gap is driven almost entirely by the Anktiva FDA outcome and the commercial trajectory that follows.

What to Watch

The FDA decision on Anktiva is the near-term event that determines everything else. Approval validates the current revenue trajectory; a rejection resets the commercial timeline. The BCG acquisition matters mainly as a complement: without Anktiva on the market, securing supply of a combination drug has limited commercial value on its own.

Free cash flow consumption matters regardless of the approval outcome. The obligations in the March 31 8-K will appear in subsequent quarterly filings. The question is how that new financial obligation interacts with a $194 million annual burn rate. The next earnings filing will show whether the three-quarter EPS improvement trend extended into the most recent period.

For a fuller picture of ImmunityBio's financial position, pipeline, and competitive landscape, run the free ImmunityBio, Inc. deep-dive →

Basis Report does not hold positions in securities discussed. This is not investment advice.